485 ROUTE 1 SOUTH, ISELIN, NJ
Outlook Therapeutics Announces Best-Efforts Public Offering of Common Stock
Supplemental Risk Factors Regarding Development and Funding Needs
Julia A. Haller, MD Steps Down from Board
Stockholder Vote Results from Annual Meeting on March 10, 2026
Other Events
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Submits Type A Meeting Request to FDA Following Complete Response Letter
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership